Michigan Medicine to help lead NIH study of extra COVID-19 vaccine dose in people with autoimmune disease

Participants will be followed for 13 months with preliminary results expected in November 2021.

Author | Noah Fromson

A Michigan Medicine physician will co-lead a National Institutes of Health study of antibody response to an additional dose of the COVID-19 vaccine in people with autoimmune diseases who did not present a strong immune response to the first round of authorized vaccination.

 
A COVID-19 vaccine given at Michigan Medicine. Credit: Michigan Medicine

The announcement comes just a few weeks after the FDA and Centers for Disease Control and Prevention recommended( that people who are moderately-to-severely immunocompromised receive a third dose of an mRNA COVID-19 vaccine. Despite making up less than 3% of the U.S. adult population, immunocompromised people account for nearly 45% of breakthrough COVID infections requiring hospitalization.

The trial will be co-led by Dinesh Khanna, M.B.B.S., M.Sc., the Frederick G.L. Huetwell professor of rheumatology and the director of the scleroderma program at Michigan Medicine. The National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, is funding the Phase 2 trial.

“Although the FDA has recently approved booster vaccines for immunocompromised patients under emergency use authorization, there are several advantages for patients to participate in this 12-month adaptive trial design,” Khanna said. “It allows us to carefully evaluate if the patients respond to the booster vaccine, continue to assess for durability of the vaccine over time and assess risk of flare of the underlying autoimmune disease.”

The trial will include approximately 600 adult participants with one of five autoimmune diseases:

  • Multiple Sclerosis
  • Pemphigus
  • Rheumatoid Arthritis
  • Systemic Lupus Erythematosus
  • Systemic Sclerosis

Trial participants, who will be followed for 13 months, must be taking immunosuppressive therapies and have demonstrated poor antibody response to an authorized COVID-19 vaccine regimen. The research team will also examine whether pausing immunosuppressive medication improves immune response to the booster shot.

“To hold or withhold the immunosuppressive therapies is an important issue for patients with autoimmune disease,” Khanna said. “On one hand, it may improve the response to the booster, and on the other hand, it may lead to disease flare. This trial will carefully evaluate this in a controlled fashion.”

For more information about the COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders trial, go to ClinicalTrials.gov and use NCT05000216 as an identifier.

 

Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

Featured News & Stories white pills falling out of orange pill bottle on a brown surface
Health Lab
Drug combination reduces breast cancer risk and improves metabolic health in rats
Researchers investigated the combined effects of bazedoxifene and conjugated estrogens in rat models as an alternative to tamoxifen.
RNA strand in purple on black background
Health Lab
A structural biologist weighs in on the tricky task of determining RNA’s shape
A recent article in Nature details why the quest to determine the shapes of RNA is difficult even for artificial intelligence.
Health Lab Podcast in brackets with a background with a dark blue translucent layers over cells
Health Lab Podcast
Polling parents on having "the talk" about puberty with their kids
Most parents agree that talking to their kids about puberty is important—but when and how to start the conversation is often less clear, a national poll suggests.
blue body with red organ lit up
Health Lab
Drug targets identified for pancreatic cancer
U-M researchers have discovered that simultaneously targeting PIKfyve and KRAS-MAPK can eliminate tumors in preclinical human and mouse models.
Campus Aerial
News Release
Breakthrough T1D U-M-OHSU Cardiorenal Center of Excellence to focus on heart and kidney disease in type 1 diabetes
reakthrough T1D, formerly JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, has awarded more than $2.8 million over three years for the Breakthrough T1D Center of Excellence at the University of Michigan and Oregon Health & Science University, creating the Breakthrough T1D U-M-OHSU Cardiorenal Center of Excellence.
pope in crowd
Health Lab
Pope Francis’ death right after Easter sounds miraculous - but patients and caregivers often work together to delay dying
Michelle Riba explains how meaning matters just as much as medicine at the end of life.